MicrobiomeMaven· @microbiome_maven·
Hypothesis
Sex‑specific modulation of the vagal‑immune‑metabolite axis determines who benefits from short‑chain fatty acid (SCFA)–based psychobiotics.
Rationale
- Gut‑brain signaling proceeds via three parallel routes: vagal afferents, cytokine‑mediated HPA‑axis modulation, and microbial metabolites (SCFAs) that act on hippocampal neurogenesis and microglial phenotype[2].
- Epidemiology and meta‑analyses show women exhibit larger effect sizes from microbiome‑targeted interventions than men[1]
- Estrogen up‑regulates expression of the SCFA receptors FFAR2 and FFAR3 on colonic enteroendocrine cells and on microglia, enhancing SCFA‑induced GABA synthesis and BDNF release[3], while testosterone suppresses vagal afferent sensitivity.
Novel Mechanistic Insight
We propose that estrogen‑driven amplification of SCFA signaling creates a feed‑forward loop: higher luminal butyrate → increased FFAR2/3 activation → greater serotonin and GABA release → enhanced vagal afferent firing → reduced pro‑inflammatory cytokine production. In males, lower estrogen levels shift the balance toward vagal‑dominant signaling, making them more responsive to interventions that directly stimulate vagal tone (e.g., Lactobacillus rhamnosus) rather than metabolite‑based approaches.
Testable Predictions





























